{
  "ticker": "LLY",
  "target_date": "2025-10-02",
  "actual_date": "2025-10-02",
  "collected_at": "2025-12-08T12:21:26.471588",
  "price": {
    "open": 813.17,
    "high": 833.24,
    "low": 811.62,
    "close": 818.647705078125,
    "volume": 4291800,
    "change_1d_pct": -0.67,
    "change_7d_pct": 9.76,
    "change_30d_pct": 16.22
  },
  "technicals": {
    "rsi_14": 65.97,
    "sma_20": 753.31,
    "sma_50": 734.07,
    "macd": 13.167,
    "macd_signal": 6.523,
    "macd_histogram": 6.643,
    "bb_upper": 807.78,
    "bb_lower": 698.85,
    "price_vs_sma20_pct": 8.67,
    "price_vs_sma50_pct": 11.52,
    "volume_ratio": 1.08
  },
  "fundamentals": {
    "market_cap": 892507848704,
    "pe_ratio": 48.779762,
    "forward_pe": 43.93623,
    "price_to_book": 37.484753,
    "price_to_sales": 15.020378,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.47,
    "pct_from_52w_low": 59.61
  },
  "macro": {
    "spy": {
      "price": 669.22,
      "change_1d_pct": 0.12,
      "change_7d_pct": 1.23
    },
    "vix": {
      "level": 16.63,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.09
    },
    "dollar_index": {
      "level": 97.85
    },
    "gold": {
      "price": 3839.7
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Why Eli Lilly Is The Lion's Share Of My Portfolio",
      "source": "SeekingAlpha",
      "datetime": 1759447570,
      "summary": "Eli Lilly\u00e2\u0080\u0099s new GLP-1 drug and diversified R&D pipeline could drive healthcare sector inflows and deliver over 40% upside. See here for more on LLY stock.",
      "url": "https://finnhub.io/api/news?id=4b2e08e689137e71c97ab431702f6dcf0001bc5b62f8f2eb7e81ef7ca39691ae"
    },
    {
      "headline": "Centene, QuidelOrtho, iRhythm, and Bio-Techne Shares Skyrocket, What You Need To Know",
      "source": "Yahoo",
      "datetime": 1759434650,
      "summary": "A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.",
      "url": "https://finnhub.io/api/news?id=fdc898911eaa47fc69ce2e4905bc3d6558c4e347ad96247869e9764a01cb4818"
    },
    {
      "headline": "agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know",
      "source": "Yahoo",
      "datetime": 1759434649,
      "summary": "A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.",
      "url": "https://finnhub.io/api/news?id=84c09a7b6806ce9ccb22a9fee3d22cd6b1be219c178c1e057faf5cf7625bb63b"
    },
    {
      "headline": "Buy Novo Nordisk Stock as Health Names Return to Favor, Analyst Says",
      "source": "Yahoo",
      "datetime": 1759423920,
      "summary": "HSBC made the call as it listed the pharma stocks it sees as best positioned to play a recovery in the sector.",
      "url": "https://finnhub.io/api/news?id=71f2be6d42a57c4dd8e4ded6c5201d00a607f13283c5cf8076e9af35ae5b3c5c"
    },
    {
      "headline": "Eli Lilly (LLY) Valuation: Assessing Growth Potential After U.S. Drug Pricing Policy Shift and Fresh Approvals",
      "source": "Yahoo",
      "datetime": 1759419732,
      "summary": "Eli Lilly (LLY) shares climbed sharply after the White House announced a new platform for Americans to buy prescription drugs directly from manufacturers at a discount. This move removed uncertainty around future drug pricing policy. See our latest analysis for Eli Lilly. This surge in Eli Lilly's s",
      "url": "https://finnhub.io/api/news?id=95d9b66fbcb96d6e5d440a3709511b369f9505f332313738cbd4f692a305b9c5"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-10-02",
      "description": "xslF345X05/form4-10022025_081019.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000019/xslF345X05/form4-10022025_081019.xml"
    },
    {
      "form": "4",
      "date": "2025-10-02",
      "description": "xslF345X05/form4-10022025_081016.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000018/xslF345X05/form4-10022025_081016.xml"
    },
    {
      "form": "4",
      "date": "2025-10-01",
      "description": "xslF345X05/form4-10012025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000011/xslF345X05/form4-10012025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-09-22",
      "description": "xslF345X05/form4-09222025_040901.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000009/xslF345X05/form4-09222025_040901.xml"
    },
    {
      "form": "4",
      "date": "2025-09-19",
      "description": "xslF345X05/form4-09192025_040901.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000007/xslF345X05/form4-09192025_040901.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}